Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic purine derivative classified as a small molecule. It is known by the code names LIE and PD004749. Structurally, it features a purine core substituted with difluorophenoxy and fluorophenyl groups as well as an isopropyl moiety. The compound has been studied primarily as an experimental inhibitor of mitogen‑activated protein kinase 14 (MAPK14), also known as p38 alpha MAP kinase. This target plays a key role in inflammatory signaling pathways and cellular responses to stress. The molecule has been co-crystallized with mouse MAPK14 in structural biology studies but does not have any approved therapeutic indications or evidence of clinical development beyond preclinical research[7][4][9]. Its main relevance lies in biochemical research on kinase inhibition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(2,6-difluorophenoxy)-N-(2-fluorophenyl)-9-isopropyl-9H-purin-8-amine.